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Abstract
African horse sickness (AHS) is a lethal viral disease of equids, which is transmitted by Culicoides midges that become
infected after biting a viraemic host. The use of live attenuated vaccines has been vital for the control of this disease in
endemic regions. However, there are safety concerns over their use in non-endemic countries. Research efforts over the last
two decades have therefore focused on developing alternative vaccines based on recombinant baculovirus or live viral
vectors expressing structural components of the AHS virion. However, ethical and financial considerations, relating to the
use of infected horses in high biosecurity installations, have made progress very slow. We have therefore assessed the
potential of an experimental mouse-model for AHSV infection for vaccine and immunology research. We initially
characterised AHSV infection in this model, then tested the protective efficacy of a recombinant vaccine based on modified
vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2).
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Introduction
African horse sickness (AHS) is a lethal viral disease of equids,
caused by an orbivirus that is closely related to bluetongue virus
(BTV). The African horsesickness virus (AHSV) is transmitted by
biting midges of the genus Culicoides, which become infected after
taking a blood meal from an infected and viraemic host. [1]. The
disease is endemic to Sub-Saharan Africa but sporadic outbreaks
have had devastating effects in Northern Africa, Europe, Middle
East and India [2,3,4,5].
The AHSV genome is composed of ten linear segments of
dsRNA, encoding seven structural proteins VP1 to VP7 and four
non-structural proteins NS1, NS2, NS3 and NS3a [6]. The AHSV
particle is organised as three concentric layers of proteins. The
outer capsid, which is composed of two proteins, VP2 and VP5,
interacts with neutralizing antibodies that are generated during
infection of the mammalian host. There are nine distinct serotypes
of AHSV, which can be distinguished in virus or serum
neutralisation tests (VNT or SNT). The identity of each serotype
is controlled primarily by the amino acid sequence of VP2, which
contains the majority of neutralising epitopes and is the principal
serotype-specific antigen of AHSV [7,8]. Animals that survive
infection by a single AHSV serotype are subsequently protected
against the homologous type, although they can still be infected by
the other serotypes. The AHSV core consists of two major proteins
that form distinct capsid layers: VP7 forms the core surface layer;
while VP3 forms the innermost ‘subcore’ shell. The subcore also
contains three minor proteins, VP1, VP4 and VP6 that form core
associated transcriptase complexes, and surrounds the 10 segments
of the viral genome (numbered segment 1 to segment 10 [Seg-1 to
Seg-10] in order of decreasing molecular weight)[6].
One of the most effective intervention strategies to combat AHS
is vaccination, allowing horses to survive in endemic regions. Live
attenuated strains of AHSV that were developed as vaccines have
been available for more than 60 years and are still routinely used
in South Africa and other endemic countries [9]. However this
type of vaccines causes viraemia in the host and therefore has the
potential to be transmitted in the field [10]. Recent experience
with similar ‘live’ BTV vaccines in Europe shows that they can
also exchange genome segments (reassort) with field strains
[11,12], potentially resulting in reversion to virulence. Since these
live vaccines work by causing ‘infection’ in the host, it is also
difficult, or impossible, to design serological assays that will reliably
distinguish (naturally) infected and vaccinated animals (‘DIVA’),
making surveillance more difficult or more expensive. These
drawbacks are considered to make the live vaccines unsuitable for
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16503use in the naı ¨ve host populations in non-endemic geographic
regions such as Europe [13].
For these reasons a number of recombinant vaccination
strategies have been pursued over the years, as an alternative to
attenuated vaccines. Baculovirus expressed AHSV capsid proteins
VP2, VP5, VP7 and VP3, either individually or combined to form
virus-like particles (VLP), have shown promising results
[14,15,16,17]. The use of recombinant pox-virus vectors express-
ing these AHSV proteins have also shown potential as vaccines for
AHS [18,19].
Although more work is needed to improve vaccines against this
disease, progress is hampered by the need to perform vaccine
efficacy studies in horses. Work with AHSV infected horses in high
biosecurity installations represents a logistical and financial
burden. For these reasons we have initiated a programme of
research based on developing an experimental mouse model for
AHS, based on recent successes with a similar model for
bluetongue [20,21].
We present the results of a pilot study using a small animal
model for AHS, based on interferon-a receptor knock-out (IFNAR
2/2) mice, and an exploration of the suitability of this system to
test AHS vaccine efficacy. We have used a recombinant modified
vaccinia Ankara virus, expressing AHS-4 VP2 (MVA-VP2), that
was previously shown to induce a virus neutralising antibody
response in ponies [19].
Results
a) Characterisation of AHSV-4 infection in IFNAR 2/2
mice. Virus dose range finder
An experimental infection with AHSV-4 was conducted in
IFNAR 2/2 mice using two different virus dose levels. Thus, two
groups of five mice were infected respectively with 10
5.8 (Group A)
or 10
4 pfu (Group B) per mouse via the subcutaneous route. Two
uninfected mice were kept as controls (Group C). Clinical signs
were monitored and virus titres in blood samples determined.
All mice infected in group A presented clinical signs, which were
evident by day 4 post-infection. These included presentation of
rough hair coat, a hunched posture and reduction of mobility,
which in some cases led to lethargy. Lacrimation and swelling of
the eyelids was also observed. Neurological signs were also seen
including ataxia, with the presentation of ‘circling gait’, and
paresis of one, two or all four limbs often leading to paralysis. One
animal from this group died of the disease, whilst two others had to
be euthanized on humane grounds due to paralysis and ataxia. In
contrast, mice in group B presented a milder clinical syndrome
characterised by reduction of mobility, which was common to all
animals, and eye swelling in just one individual. There were no
neurological signs present and all animals infected in this group
survived. Controls in group C remained healthy until the end of
the study.
Mice in group A developed a significantly higher viraemia
(mean virus titres) than those in group B (Fig. 1). Furthermore,
animals with the highest viraemia titres (ranging from 794 to
2,818 pfu/ml) at the peak of the infection on day 4, either died or
presented severe neurological signs, indicating a correlation
between the level of viraemia and the severity of the infection.
The statistical analysis of the percentage of survival between
groups A and B using the Logrank test indicated significant
differences (p,0.05). Pathological examinations were performed
on the three mice in group A that did not survive the experiment.
Macroscopic lesions were present in the spleen, liver, kidneys,
brain and lungs. In each case the spleen appeared congested and
very enlarged, approximately 3 times larger than normal. Kidneys
and liver were also congested and enlarged. Lungs appeared
congested and in some cases surface ecchymotic haemorrhages
were observed. The brain of these animals looked slightly
congested, almost normal.
Microscopically, the spleen showed a loss of its normal structure
and it was not possible to observe the separation between red and
white pulp due to a marked lymphoid depletion (Fig. 2a, b). In
addition, there was abundant presence of amyloid. Two main
features were observed in the liver, namely the presence of a rich
inflammatory mononuclear infiltrate in the periportal spaces as
well as randomly distributed foci of necrosis. The latter consisted
of cell debris together with apoptotic and necrotic hepatocytes
Figure 1. Survival rates and viraemia in IFNAR 2/2 mice infected with AHSV. Groups of five mice were infected with AHSV-4 using 10
4
(Group A) or 10
5.8 (Group B) pfu/mouse. Viraemia is represented by histograms expressing mean pfu/ml values of each of the samples collected for
each day. Survival rates are represented by lines and express the percentages of surviving mice per day.
doi:10.1371/journal.pone.0016503.g001
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presented enlarged interalveolar spaces which were filled with an
abundant mononuclear cell infiltrate, consistent with a viral
interstitial pneumonia (Fig. 3a, b). All three mice presented
meningoencephalomyelitis, which was significantly less marked in
the animal that died earlier on day 7 than in the two euthanased a
day later. There was a marked inflammatory mononuclear
infiltrate in the meninges, presence of perivascular leukocyte cuffs
randomly distributed in the brain parenchyma as well as multiple
foci of microgliosis and neuronal apoptosis (Fig. 3c, d).
b) Protective efficacy of MVA-VP2 vaccinated IFNAR 2/2
against AHSV-4 challenge
Once the challenge infection of IFNAR 2/2 mice with AHSV-
4 had been characterised and that doses in the order of 10
6 pfu/
mouse induced clinical signs, viraemia and significant levels of
lethality, we evaluated the protective efficacy of a recombinant
MVA expressing VP2 of AHSV-4 (MVA-VP2). In earlier studies
this recombinant MVA virus was shown to induce virus
neutralising (VN) antibodies against AHSV-4 in ponies [19]. Six
IFNAR 2/2 mice (M1–M6) were vaccinated by the intra-
peritoneal route on days 0 and 28 with 10
7 pfu of MVA-VP2 per
mouse. These animals and six unvaccinated IFNAR 2/2 control
mice (C1–C6) were subsequently challenged on day 35 with
10
6 pfu of AHSV-4. Blood samples were collected at regular
intervals for virus titration and assessment of antibody responses
by VN assays and VP7- ELISA. The clinical signs, percentage
survival, virus titres and Ct values determined by real-time RT-
PCR in blood, were compared between the two groups of animals,
to evaluate the level of protective immunity afforded by MVA-
VP2 vaccination.
The percentage survival and viraemia showed that all of the
vaccinates survived the challenge and were negative for viraemia
(Fig. 4).In contrast, the control mice group presented a survival
rate of 50% and were viraemic for a number of days post-
infection. The statistical analysis of the survival rates using the
Logrank test indicated significant differences (p,0.05) between
immunized and nonimmunized groups. All of the MVA-VP2
vaccinated animals were also protected from clinical signs (data
not shown) and were completely healthy until the end of the study
period. In contrast, all the unvaccinated control mice developed
clinical signs similar to those described earlier during the previous
challenge experiment. One of the unvaccinated control animals
died on day 4 and two others were euthanized due to severe
neurological signs on days 8 and 11 post-infection. The statistical
analysis of the survival rates using the Logrank test indicated
significant differences (p,0.05) between immunized and non-
immunized groups. Likewise, comparison of viraemia titres
between vaccinates and controls showed statistical significance
by the Student’s t-test (p,0.05).
Post-mortem examination of control mice revealed the same
type of lesions as observed in the previous challenge experiment
performed with AHS-4. In addition to hematoxylin-eosin staining,
immuno-fluorescence experiments were used to demonstrate the
presence of AHSV antigen in tissues. These were performed on
paraformaldehyde fixed cryosections of AHSV-4 challenged mice
and uninfected control mice. A rabbit polyclonal antiserum raised
against AHSV- VP7 was used as primary antibody. Distribution of
antigen in spleen was widespread and uniform, whereas in the liver
it was observed as scattered foci (Fig. 5 and 6).
Data from a semi-quantitative analysis of the virus content in
blood samples by real-time RT-PCR were compared with virus
isolation data (Table 1). Only two of the vaccinated mice produced
a Ct value for 1 and 2 days respectively. In contrast, all except one
of the blood samples collected from control mice, were positive by
the RT-PCR assay.
Analysis of antibody responses was performed by VN test and
VP7-ELISA. All of the mice vaccinated with MVA-VP2 developed
Figure 2. Histopathology of spleen and liver from AHSV-4 infected IFNAR 2/2 mice. Liver and Spleen. Hematoxylin-eosin staining.
Representative examples of the microscopic lesions found on liver and spleen of AHSV-4 infected IFNAR 2/2 mice are shown. Spleen and liver
samples were collected from IFNAR 2/2 mice, on day 7 post-infection with AHSV-4. The spleen shows loss or its normal structure (a) and abundant
deposits of amyloid (a,b). The liver presents a mononuclear inflammatory infiltrate in the portal triad (c) and foci of necrosis (d).
doi:10.1371/journal.pone.0016503.g002
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of the microscopic lesions found on lung and brain of AHSV-4 infected IFNAR 2/2 mice are shown. Spleen and liver samples were collected from
IFNAR 2/2 mice, on day 7 post-infection with AHSV-4. The lung tissue presented hyperemia, enlargement of the interalveolar septa and a
pronounced mononuclear infiltrate (a,b). Images of brain show areas of microgliosis (c) and perivascular cuffing of mononuclear cells (c,d).
doi:10.1371/journal.pone.0016503.g003
Figure 4. Protection of MVA-VP2 vaccinated IFNAR 2/2 mice against AHSV-4 challenge. Non-vaccinated control and MVA-VP2 vaccinated
mice were challenged with AHSV-4. Survival rates (dotted lines) and viraemia titres (grey histograms) of both groups were compared. Each histogram
represents the mean values of the viral titer of six animals, and standard deviations are shown as error bars. Asterisks indicate statistical significance
calculated using the Student’s t test (p,0.05).
doi:10.1371/journal.pone.0016503.g004
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Following challenge, both the vaccinated and surviving control
mice presented VN antibodies on day 23 post-infection (data not
shown). The results of the VP7-ELISA assay of the serum samples
from the vaccinated and challenged mice, are displayed in figure 7.
As expected, all of the mice, from both groups, were negative for
VP7-specific antibodies up to the day of challenge. The three
surviving controls all developed VP7-specific antibodies by day 23
post-infection, indicating the animals immune system responded to
the antigenic exposure. In contrast, only one of the vaccinated
mice became positive by ELISA after challenge. This animal,
MVA-VP2 (2), was the vaccinate whose blood was positive by RT-
PCR on two consecutive days. These results indicated that all of
the vaccinates, except M2, developed ‘sterile’ immunity to AHSV-
4(09) reducing virus replication to such low levels that no-
detectable immune response was developed to AHSV-VP7.
Discussion
Most of the recent African horse sickness research has focused
on development of vaccine technologies that are safer, effective
and compatible with their application in non-endemic countries.
However, any new vaccine need to be evaluated in protective
efficacy studies. Such experiments are difficult to perform in horses
(the target species), due to high costs and logistic difficulties
relating to the use of statistically significant number of animals in
high bio-containment. For these reasons we have tested a mouse
model for AHS, similar to that recently used for bluetongue
[20,21]. This system has the potential to dramatically increase
research outputs and facilitate the testing of scientific hypotheses
related to pathogenicity, immunology and vaccinology, which can
then be verified with studies in the target species.
Laboratory animals, notably mice, have been used for many
years to study infections with AHSV. Intracerebral inoculation of
suckling mice is one of the primary techniques used to isolate
AHSV from clinical specimens. But apart from this diagnostic
application, mouse experimental mouse models have also been
used in studies of AHSV pathogenicity and vaccination [22,23].
These experiments described in these studies were previously
performed in Balb/C mice although the results varied depending
on the strain of virus used and lethality was often very low or
absent in most cases. On some occasions, when the virus was
Figure 5. Detection of AHSV- antigen in liver tissues of AHSV-4 infected IFNAR 2/2 mice. Livers of normal uninfected (a) and AHSV-4
infected (b) mice were processed for immuno-fluorescence as indicated in Materials and Methods. The presence of AHSV antigen in the liver (green
fluorescence) accumulates in foci of cells that resemble the foci of necrosis observed in hematoxylin-eosin sections.
doi:10.1371/journal.pone.0016503.g005
Figure 6. AHSV- antigen in tissues of AHSV-4 infected mice. Spleen. Spleens of normal uninfected (a) and AHSV-4 infected (b) mice were
processed for immuno-fluorescence as indicated in Materials and Methods. Antigen staining (green fluorescence) can be observed ramdomly
distributed throughout the spleen parenchyma.
doi:10.1371/journal.pone.0016503.g006
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of fatalities was observed that was sufficient for vaccine efficacy
studies. However, these routes of infection are very different to
that used by Culicoides transmitted AHSV in the natural host.
Recently, Calvo-Pinilla and co-workers successfully used
IFNAR 2/2 mice as a model for bluetongue [20,21]. In their
studies, BTV infected IFNAR 2/2 mice, but not C57BL/6 mice,
developed consistently clinical signs, with high mortality and high
virus titre viraemia. The pathology in these animals appeared to
be similar to that found in the natural host. We have explored the
potential of this animal system for studies of AHSV infection and
found that mortality rates, clinical signs and viraemia levels are
appropriate for vaccine efficacy studies. Furthermore, the
pathology of the AHSV infected mice, with the exception of the
central nervous system lesions, resemble those found in AHSV
infected horses. Hemorrhages and inflammatory changes in the
lung, splenomegalia and congestion of other internal organs such
as the liver are common pathological findings in horses infected
with AHSV [1,24]. Furthermore, immuno-fluorescence results of
AHSV infected IFNAR 2/2 mouse tissues, demonstrated the
expression of AHS antigens particularly in the spleen, suggesting
this organ contains a high viral load. This feature is probably
shared with AHSV infected horses, since the spleen is the
preferred organ for making an etiological diagnosis of AHS in
the horse (post-mortem) (OIE, 2010). The presence of neurological
signs and lesions in the nervous system is a feature that has not
frequently been observed in AHSV infected horses. However, the
virus used for challenge in these experiments derives from a mouse
brain isolate of AHSV and may have retained/aquired a certain
level of neurotropism. It has to be mentioned that most isolates of
AHSV are derived from mouse brain, since this has been
traditionally the preferred virus isolation method. This is
particularly true for the reference strains of AHSV, such as the
virus we have used for our studies.
The Madrid 87 strain used in our studies was chosen because
the VP2 gene employed to construct the MVA-VP2 vaccine virus
was derived from it. This virus was initially isolated in mouse
brain, further passaged once in mouse brain and three times in
BHK before used in our mouse experiments. This virus strain,
although obviously not exactly the same stock, was used in
challenge experiments in horses inducing typical severe signs of
AHS including death (10).
We used a subcutaneous route of infection because it most
closely resembles the natural route of entry/infection during the
natural AHSV infection cycle. BTV infection of IFNAR 2/2
mice via this route induces similar levels of lethality, viraemia and
pathology to those generated via an intravenous route (Javier
Ortego, personal communication). However, it is uncertain
whether the route of challenge would influence the outcome of
AHS virus infection in IFNAR 2/2 mice. Vaccination was
performed by the intraperitoneal route since this is a well
established route and it had been used successfully in IFNAR
2/2 mice vaccinated with recombinant MVA (20).
Interferon alpha (IFN-a) can play an important role in the
innate immune response against viruses. IFN-a is produced by
plasmacytoid dendritic cells in response to viral dsRNA, which
binds to cellular receptors of neighbouring cells, stimulating of a
series of antiviral mechanisms that help to clear infection. It is not
known yet whether AHSV specifically induces IFN-a, or if IFN-a
plays an important role in controlling AHSV infection, but
evidence from studies with BTV suggest this possibility [25]. Our
study also points towards this, since previous experimental
infection of Balb/C mice with AHSV by the subcutaneous route
consistently failed to induce clinical signs or mortality [23], which
contrasts with the significant pathology and mortality (50%)
observed in AHS virus infected IFNAR 2/2 mice. However,
more work, is needed to elucidate the interaction of AHSV with
the host’s innate immune system.
One concern over the use of IFNAR 2/2 mice in vaccination
studies is the potentially detrimental effect that the absence of IFN-
a signalling could have on the adaptive immune response of the
host. However, vaccination studies in IFNAR 2/2 mice with
non-infectious agents, such as recombinant vesicular stomatitis
virus glycoprotein, have shown that IFNAR 2/2 mice can
Table 1. Detection of AHSV-4 RNA by RT-PCR in blood samples from control (C1-C6) and MVA-VP2 vaccinated (M1-M6) animals
after challenge.
Days post-infection
Animals 1 2 3 4 5 6 7 8 9 10 11 12 13 14
C1 n.s. 37.33 n.s. 27.56 n.s. n.s. 30.29 n.s. 29.04 n.s. 32.87 n.s. n.s. 30.88
C2 n.s. 32.64 n.s. 33.08 n.s. n.s. 26.68 n.s. 29.17 n.s. 30.28 n.s. n.s. 0
C3 n.s. 37.25 n.s. 31.44 n.s. n.s. 28.54 n.s. 30.75 n.s. 30.53 n.s. n.s. 32.05
C4 n.s. 34.86 n.s. 25.97 n.s. n.s. { n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
C5 n.s. 35.67 n.s. 30.57 n.s. n.s. 27.44 n.s. { n.s. n.s. n.s. n.s. n.s. n.s.
C6 n.s. 30.57 n.s. 31.67 n.s. n.s. 28.71 n.s. 28.77 n.s. { n.s. n.s. n.s. n.s.
M1 n.s. 0 n.s. 0 n.s. n.s. 0 n.s. 0 n.s. 0 n.s. n.s. 0
M2 n.s. 0 n.s. 35.58 n.s. n.s. 37.45 n.s. 0 n.s. 0 n.s. n.s. 0
M3 n.s. 0 n.s. 38.13 n.s. n.s. 0 n.s. 0 n.s. 0 n.s. n.s. 0
M4 n.s. 0 n.s. 0 n.s. n.s. 0 n.s. 0 n.s. 0 n.s. n.s. 0
M5 n.s. 0 n.s. 0 n.s. n.s. 0 n.s. 0 n.s. 0 n.s. n.s. 0
M6 n.s. 0 n.s. 0 n.s. n.s. 0 n.s. 0 n.s. 0 n.s. n.s. 0
Results are expressed as Ct values. Values of 0 indicate no Ct value was recorded.
Results in bold indicate that virus was isolated in tissue culture for that particular sample on that day.
{: Death.
n.s.: no sample collected.
doi:10.1371/journal.pone.0016503.t001
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lymphocyte responses [26]. Mice lacking IFN-a responses could
not cope with most viral infections [27] but the lack immune
responses observed in these animals, such the abscence of a
cytotoxic T-lymphocyte response of lymphochoriomeningitis virus
infected IFNAR 2/2 mice, was not due to a deficient immune
system. Likely, it is a reflection of the exhaustion of virus-specific
activated T cells following exposure to high doses of rapidly
replicating virus, favored by the absence of IFN-a [28]. From this
it follows that vaccination of IFNAR 2/2 mice with a highly
attenuated virus will result in a complete immune response. This
has been described for IFNAR 2/2 mice infected with the
attenuated Lancy strain of vaccinia virus [26].
In our studies we have used the highly attenuated vaccinia
MVA strain as a vaccine vector and showed that IFNAR 2/2
mice vaccinated with MVA-VP2 developed VN antibodies and
protective immunity against AHSV. The levels of immunity are
very high since none of vaccinates presented viraemia and only
two animals produced blood samples that were positive by highly
sensitive real-time RT-PCR techniques. Furthermore, only one
vaccinate developed VP7 specific antibodies after challenge
suggesting that the vaccinates were exposed to only very low
levels of virus antigen. Our data confirms that a lack of IFN-a in
mice did not affect the immune responses elicited by vaccination
with an MVA based vaccine. These findings are consistent with
similar studies performed with MVA based vaccines against BTV
[20].
The protective effect against AHSV infection that was provided
by MVA-VP2 vaccination was not surprising. We have previously
demonstrated induction of VN antibodies in ponies vaccinated
with the same recombinant virus [19] and others have succeeded
in protecting horses against AHS using VP2 based vaccines, either
Figure 7. AHSV-VP7 specific antibody responses of unvaccinated and MVA-VP2 vaccinated IFNAR 2/2 mice after vaccination and
challenge with AHSV-4. Serum samples collected from the mice at days 0 (first vaccination), 21(second vaccination), 35(challenge) and 23 post-
challenge (23 p.i.) were analysed by the VP7-ELISA. Results are expressed as percentage of blocking and are represented by histogram bars. The
positive threshold for a positive result is set at 50% and is represented in the graphs by a red horizontal line.
doi:10.1371/journal.pone.0016503.g007
Table 2. Virus neutralisation titres of serum samples collected
from the control (C1 – C6) and vaccinated (M1 – M6) mice at 4
different time points during the study.
Animals Day 0 Day 28 Day 35 Day 23 p.i.
C1 neg neg neg 251
C2 neg neg neg 126
C3 neg neg neg 112
C4 neg neg neg {
C5 neg neg neg {
C6 neg neg neg {
M1 neg neg 5* 112
M2 neg neg 5 447
M3 neg neg 25 56
M4 neg neg 14 63
M5 neg neg 16 100
M6 neg neg 5* 56
p.i. post-infection (neg) indicates negative result for neutralization.
(*) Indicates that samples could not be titrated due to the low volume of serum.
({) Samples not available due to death of the animal during challenge.
doi:10.1371/journal.pone.0016503.t002
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virus vectors [18,29]. VP2 is the main target of neutralising
antibodies on AHSV, although neutralising epitopes have also
been identified on VP5 of AHS virus serotype 4 [30] and this
protein seems to exert some conformational effect on VP2
epitopes. There are BTV and AHSV vaccination studies showing
that co-expression of both outer capsid proteins induces a more
effective protective immunity than either protein alone. Although
we have not used a dual expression vector vaccine expressing VP2
and VP5, it is clear from our studies that VP2 alone was indeed
able to provide full protection in the IFNAR 2/2 model.
Moreover, vaccination and challenge studies using baculovirus
expressed AHSV-5 VP2 [14], or a recombinant vaccinia virus
expressing VP2 [29] showed that VP5 was not critical for
induction of a protective response in horses. More work is needed
to further understand the molecular nature of the VN epitopes on
AHSV and the importance of VP2-VP5 interactions in induction
of full protective immunity.
Our study confirms the potential MVA-VP2 as a vaccine
against AHSV. This vector vaccine stimulated VN antibodies in
ponies, shows protective capacity in the IFNAR 2/2 model and
because it is based on a restricted antigenic repertoire of the virus,
is suited for differential diagnostics with an appropriate differential
ELISA test (DIVA strategy). A VP7-ELISA that has already been
developed as a diagnostic assay for AHSV specific antibodies could
serve this purpose, since the control animals that survived the
infection all presented VP7 specific antibodies, in contrast to those
that had only been vaccinated with MVA-VP2, which showed no
response to VP7. Most of the vaccinated animals that were
subsequently also challenged with AHSV, still failed to develop
VP7 specific antibodies, because they did not become infected.
However, in one case (M2 in Figure 7) a positive ELISA result was
recorded, although this reflected a low level infection post
challenge. Further studies in horses need to be performed to
confirm the protective efficacy of MVA-VP2 vaccination in the
target species, as well as the application of suitable differential
diagnostic tests. However these experiments can be initiated
knowing that the vaccinates are likely to survive and would be
spared the worst clinical signs of AHS.
In conclusion, we have shown that IFNAR 2/2 mice can be
infected by a subcutaneous route, inducing clinical signs, lethality,
viraemia and pathology that are appropriate for immunology and
pathogenesis studies of AHSV. To gain further evidence of the
potential of this system, we conducted a vaccination and challenge
experiment in this model, demonstrating the protective efficacy of
the recombinant MVA-VP2 prototype vaccine. More work is
needed to refine and improve this model and to determine
whether our findings can be extended to other strains and
serotypes of AHSV. This experimental system will facilitate work
on individual and even cross-reactive vaccines as well as other
aspects of AHS research.
Materials and Methods
Virus and cells
Baby hamster kidney cells (BHK-21), and Vero cells, obtained
from the Institute for Animal Health Central Service Unit, were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 2 mM glutamine, antibiotics and 10% fetal calf
serum (FCS). Standard virus titrations were performed in Vero
cells. The AHSV-4 virus stock used for challenge and for virus
neutralisation tests was derived from a Spanish isolate of AHSV
(Madrid-87) passaged twice in mouse brain and three times in
BHK-21 cells. Virus stocks were generated by infection of
confluent BHK-21 cells with this virus using a multiplicity of
infection (MOI) of 0.1. When total cytopathic effect (CPE) was
visible, the cells and supernatants were harvested and centrifuged.
The supernatant was kept at 280C.
The MVA-VP2 virus used in this study was derived by single
passage in the chicken embryo fibroblast cell line DF-1 of the
construct described elsewhere [19]. The DF-1 cells were obtained
from the Microbiological Services of the Institute for Animal
Health.
Mice
All experiments with live animals were performed under the
guidelines of the European Community (86/609) and were
approved by the Centro de Investigacio ´n en Sanidad Animal,
INIA, Madrid (CISA), reference number: 2008/007. Mice were
maintained under pathogen-free conditions and allowed to
acclimatize to the biosafety level 3 (BSL3) animal facilities at
CISA for 1 week before use in our experiments.
Animal inoculation and processing of samples
For challenge, mice were innoculated subcutaneously with the
challenge strain. Mice were examined for clinical symptoms daily.
Animals showing severe symptoms were humanely euthanized.
These clinical signs included: severe ataxia, paralysis, circling gait,
lethargy and any other condition that affected the animals capacity
to eat or drink. Whole blood was collected in EDTA from all
animals at regular intervals after inoculation for virus isolation.
200 ml of blood was washed in PBS and resuspended in 900 mlo f
water to lyse the cells. 100 ml of 10x PBS was added to the sample
and 10-fold dilutions of this material were used for quantification
of viraemia using a standard plaque assay on Vero cells as
described [20,21].
Murine immunizations
IFNAR 2/2 mice were immunised by two intraperitoneal
injections of MVA-VP2 administered on days 0 and 28 using
10
7 pfu/mouse. Mice were bled for serum collection on days 0, 28,
35 (day of challenge) and 23 days post-challenge.
Serology
Sera were tested for neutralising antibodies using standard
procedures using AHSV-4.Samples were preliminary screened for
neutralising activity at a single dilution of 1/5. Positive samples
were further titrated to determine the VN titre of the sera. Briefly,
in a microtitre flat bottomed plate, 50 ml of serum samples
dilutions in DMEM without bovine serum were incubated for
1 hour at 37uC with 50 ml of 100 TCID50 of AHSV. A virus
titration was included to check the virus dose of the assay was
correct and a titration of horse antisera positive for AHSV-4 VN
antibodies were included in the assay as positive controls. Vero
cells were added at 2610
4 cells/well/100 ml and plate was
incubated at 37uC for 3 days. Wells were observed for
development of cytopathic effect.
A commercial blocking ELISA test (Ingezim 14AHSK3,
INGENASA, Madrid, Spain) was used to detect the presence of
VP-7 specific antibodies in serum. Manufacturer recommenda-
tions were used.
Histopathology
Samples from different tissues and organs were taken and fixed
in 10% buffered formalin (pH 7.2) for histopathological studies.
After fixation, samples were dehydrated through a graded series of
alcohol to xylol and embedded in paraffin wax. Sections of 4-
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histopathological analyses.
In addition, tissues were also cryopreserved in OCT, cut in 7
micron-thick sections, fixed in 4% paraformaldehyde and
processed for immuno-fluorescence. Briefly, a rabbit antiserum
raised against AHS-9 -VP7 crystals was diluted 1/1000 in PBS
containing 0.5% bovine serum albumin (PBS-A) and applied to
the sections. After 1 hour incubation at room temperature (RT),
the slides were washed in PBS and incubated with 488-Alexafluor
conjugated anti-rabbit IgG (Invitrogen) diluted 1/200 in PBS-A. A
final wash in PBS preceded a 5 minute incubation step with
rhodamin-phalloidin and a 5 minute incubation step with DAPI.
Sections were then mounted and observed by confocal microsco-
py.
RT-qPCR
Total RNA was extracted from blood samples processed as
indicated above using BioRobot Universal (Qiagen). After heat
denaturation the RNA was tested by real time RT-PCR on an
Mx3005p machine (Stratagene, Agilent Technologies) essentially as
described by Shaw et al. [31], using on this occassion serogroup-
specific primers and probe targeting AHSV-4 genome segment 1
(assay under commercialization with LSI, France) and analysed
using themanufacturersoftware (Stratagene,Agilent Technologies).
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